Herein, we show the potential of CA IX/XII inhibitor, SLC-0111, to sensitize HNSCC tumor cells and xenografts to Cis-Pt treatment increasing reduction of tumor growth and invasiveness. Here, CA9 is linked to head and neck squamous cell carcinoma.